Welcome to our dedicated page for Lemaitre Vasculr SEC filings (Ticker: LMAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LeMaitre Vascular, Inc. filings document a Nasdaq-listed medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Recent Form 8-K reports furnish quarterly operating and financial results, dividend-related updates, and related press release exhibits.
Proxy and governance filings cover board structure, director elections, executive compensation, advisory say-on-pay matters, and shareholder voting results. The filings also identify the company’s common stock, par value, Nasdaq Global Market listing under LMAT, and related public-company disclosure controls.
LeMaitre Vascular director Martha Shadan reported equity-based compensation on common stock. On February 26, 2026, she acquired 476 shares of common stock at a price of $0.0000 per share as a grant or award. She also acquired 1 additional common share through the exercise of a dividend equivalent right linked one-for-one to common stock. These transactions stem from a Performance Share Unit award originally granted on December 6, 2024, which vested one-third upon satisfaction of its performance condition on February 26, 2026, with the remaining portions scheduled to vest in equal annual installments on the grant date anniversaries over the next two years.
LeMaitre Vascular director John A. Roush reported equity awards and vesting activity, not open‑market trades. On February 26, 2026, he received a grant of 476 shares of common stock and 1 share from the exercise of dividend equivalent rights, bringing his directly held common stock to 3,942 shares. Related derivative dividend equivalent rights totaled 2.8963 following settlement linked to a Performance Share Unit (PSU) award granted on December 6, 2024, which vested one‑third when the performance condition was met, with the remainder vesting in equal annual installments over the next two years. An additional 181 shares are held indirectly by his spouse.
LeMaitre Vascular director Bridget A. Ross reported acquiring company stock through equity awards. On February 26, 2026 she received 476 shares of common stock upon partial vesting of a performance share unit award, plus 1 share released from dividend equivalent rights, bringing her direct holdings to 3,942 shares.
LeMaitre Vascular director John James O'Connor reported equity awards and related conversions, not open-market trading. On February 26, 2026 he acquired 476 shares of common stock at $0.0000 per share as a grant or award, bringing his direct common stock holdings to 62,826 shares, then to 62,827 shares after a related derivative conversion.
He also exercised 1 dividend equivalent right and converted it into 1 share of common stock, and now holds 2.8963 dividend equivalent rights. Footnotes explain these transactions relate to a Performance Share Unit award granted on December 6, 2024, which vested one-third upon satisfaction of its performance condition on February 26, 2026, with the remainder vesting in equal annual installments over the next two years.
LeMaitre Vascular director Lawrence J. Jasinski reported equity awards tied to performance share units. On February 26, 2026, he acquired 476 shares of common stock at no cost upon settlement of a PSU award granted on December 6, 2024, plus 1 additional common share from a derivative exercise.
The PSU award vested one‑third when the performance condition was determined satisfied on February 26, 2026, with the remaining two‑thirds vesting in equal annual installments over the next two years. Related dividend equivalent rights, economically equal to common stock, now total 2.8963 rights.
LEMAITRE VASCULAR director Joseph P. Pellegrino Jr. reported share acquisitions tied to equity compensation, not open-market buying or selling. On February 26, 2026, he received 1,893 shares of common stock as part of a performance share unit (PSU) award granted on December 6, 2024, after 25% of the award vested upon satisfaction of a performance condition.
He also acquired 4 dividend equivalent rights, which were exercised into 4 shares of common stock at a price of $0.00 per share. Each dividend equivalent right is the economic equivalent of one share of common stock and was released in connection with the PSU vesting. Following these transactions, he directly owned 12,080 shares of common stock and 11.4826 dividend equivalent rights, reflecting routine equity-based compensation rather than discretionary trading.
LeMaitre Vascular senior vice president Trent G. Kamke reported multiple equity transactions. On February 27, 2026, he completed an open-market sale of 1,044 shares of common stock at $110.29 per share, after which he directly held 6,677 common shares.
On February 26, 2026, he acquired 1,051 common shares at no cost from the settlement and partial vesting of a performance share unit award, plus 2 additional shares from related dividend equivalent rights. Also on that date, 93 shares were withheld to cover tax obligations tied to the PSU vesting.
LeMaitre Vascular (LMAT) president and director David B. Roberts reported multiple equity transactions. The largest was an open-market sale of 8,464 shares of common stock at a weighted average price of $106.8003 per share, leaving him with 17,979 shares directly owned after that sale.
On the prior day, he acquired common stock through the vesting and settlement of performance share unit (PSU) awards and related dividend equivalent rights, including grants of 1,514 shares and 146 shares at no cost, plus small amounts from dividend equivalents. The company also withheld 134 shares and 13 shares to cover tax obligations upon PSU vesting, which are reported as exempt dispositions.
LEMAITRE VASCULAR INC Chairman and CEO George W. LeMaitre reported a mix of stock sales, awards, and transfers. He sold an aggregate 205,930 shares of common stock in open-market transactions on February 26, 2026 and March 2, 2026, at weighted average prices of $106.7557 and $107.8137 per share, including sales made under a Rule 10b5-1(c) trading plan adopted on March 10, 2025.
On February 26, 2026, he received 5,609 shares upon settlement of a performance share unit award, plus 13 shares from related dividend equivalent rights, and 13 additional common shares from a derivative conversion. The company withheld 496 shares to cover tax obligations on the vesting PSUs.
On March 2, 2026, he made a bona fide gift transfer of 5,000 common shares. Separately, 33,400 shares are held by an irrevocable trust for the benefit of his children, for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
LeMaitre (LMAT) reported an insider sale. The filing shows George W. LeMaitre sold 150,000 shares of common stock on 02/26/2026 for $16,013,350.00.
The Form 144 lists securities-to-be-sold entries and prior issuer-side grants and exercises; timing and other quantities are included in the filing.